Studies demonstrating the insulinotropic and glucose-lowering effects of GLP-1 in islet β cells combined with the hyperglycemic effects of GLP-1R antagonism stimulated the search of GLP-1R agonists for the treatment of T2D (71). The gene discussed is GCG; the disease is type 2 diabetes mellitus.